David Gryska - Incyte CFO, Executive Vice President
| INCY Stock | USD 52.82 0.10 0.19% |
President
Mr. David W. Gryska is no longer Chief Financial Officer, Executive Vice President of Incyte Corporation effective on 12 31 2018. He joined Incyte as Executive Vice President and Chief Financial Officer in October 2014. Prior to joining Incyte, Mr. Gryska served as an independent consultant and as a member of several public company boards of directors. Mr. Gryska served as the Chief Operating Officer and a Director of Myrexis, Inc., a biotechnology company, from May 2012 to December 2012. From December 2006 to October 2010, Mr. Gryska served as Senior Vice President and Chief Financial Officer of Celgene Corporationrationration, a biopharmaceutical company. From October 2004 to December 2006, Mr. Gryska was a principal at Strategic Consulting Group. Previously, Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from 2000 to 2004, and as Vice President of Finance and Chief Financial Officer from 1998 to 2000. From 1993 to 1998, Mr. Gryska served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst Young LLP since 2014.
| Age | 61 |
| Tenure | 10 years |
| Professional Marks | CPA |
| Address | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 |
| Phone | 302 498 6700 |
| Web | https://www.incyte.com |
Incyte Management Efficiency
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Carissa Rodeheaver | First United | 48 | |
| Randolph Richards | Chevron Corp | 60 | |
| R Pate | Chevron Corp | 51 | |
| Robert Pate | Chevron Corp | 57 | |
| Navin Mahajan | Chevron Corp | ||
| Joseph Geagea | Chevron Corp | 60 | |
| Robert Fisher | First United | 45 | |
| Jeannette Fitzwater | First United | 53 | |
| Eimear Bonner | Chevron Corp | 49 | |
| Pierre Breber | Chevron Corp | 60 | |
| M Nelson | Chevron Corp | 53 | |
| Dale Walsh | Chevron Corp | 58 | |
| Adalberto Cantu | Home Federal Bancorp | 74 | |
| Colin Parfitt | Chevron Corp | 55 | |
| Rudy Torjak | Citizens Financial Corp | 63 | |
| Glen Brown | Home Federal Bancorp | 60 | |
| Anoop Kumar | Chevron Corp | N/A | |
| David Payne | Chevron Corp | N/A | |
| James Barlow | Home Federal Bancorp | 56 | |
| Robin Murray | First United | 55 | |
| Charles Withee | Provident Bancorp | 51 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 |
Incyte Leadership Team
Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Senior Vice President and Chief Medical Officer | ||
| Paul Trower, Principal Accounting Officer and VP of Fin. | ||
| Thomas Tray, Chief Finance | ||
| Pamela Murphy, Vice Communications | ||
| Eric Siegel, Executive Vice President General Counsel | ||
| Vijay Iyengar, Executive Vice President Global Strategy and Corporate Development` | ||
| Reid Huber, Chief Scientific Officer and Executive VP | ||
| Richard Levy, Executive Vice President Chief Drug Development and Medical Officer | ||
| Christine Chiou, Head Relations | ||
| PharmD MBA, Executive America | ||
| JeanJacques Bienaime, Independent Director | ||
| Paul Brooke, Independent Director | ||
| Maria Pasquale, Executive Vice President General Counsel | ||
| Christiana Stamoulis, CFO, Executive Vice President | ||
| Steven MD, Executive Officer | ||
| Julian Baker, Independent Vice Chairman of the Board | ||
| Sheila Denton, Executive Counsel | ||
| Michael Booth, VP - Investor Relations | ||
| David Gryska, CFO, Executive Vice President | ||
| Paul Friedman, Director | ||
| Wenqing Yao, Executive Vice President - Discovery Medicinal and Process Chemistry | ||
| Jacqualyn Fouse, Director | ||
| Paula Swain, Executive Resources | ||
| Paul Clancy, Director | ||
| Wendy Dixon, Independent Director | ||
| Michael Morrissey, Executive Operations | ||
| Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee | ||
| Barry Flannelly, Executive Vice President - Business Development and Strategic Planning | ||
| Dashyant Dhanak, Executive Vice President Chief Scientific Officer | ||
| Christiana MBA, Executive CFO | ||
| Maria JD, Gen VP | ||
| MBA MBA, Ex America |
Incyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 8.35 B | ||||
| Shares Outstanding | 224.53 M | ||||
| Shares Owned By Insiders | 1.58 % | ||||
| Shares Owned By Institutions | 98.42 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Earning | 19.17 X |
Incyte Investors Sentiment
The influence of Incyte's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Incyte. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Incyte's public news can be used to forecast risks associated with an investment in Incyte. The trend in average sentiment can be used to explain how an investor holding Incyte can time the market purely based on public headlines and social activities around Incyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Incyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Incyte's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Incyte's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Incyte.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Incyte in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Incyte's short interest history, or implied volatility extrapolated from Incyte options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.324 | Earnings Share 2.65 | Revenue Per Share 16.526 | Quarterly Revenue Growth 0.093 | Return On Assets 0.0646 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.